Artificial Antibody Mimetics
人工抗体模拟物
基本信息
- 批准号:6578413
- 负责人:
- 金额:$ 14.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-03-13 至 2004-02-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
Among the many mechanisms by which cancer arises, it is now appreciated that inappropriate phosphorylation is a key pathway. Detection agents capable of binding discrete phosphoproteins with high specificity will be important tools for research, diagnostics, and drug discovery. Currently available detection agents are most commonly antibodies or antibody mimetics made using biologic or enzymatic systems. Detection agents that rely on biology or enzymes suffer from several inherent shortcomings that include a restricted biomolecule repertoire that is time-consuming and costly to manufacture. Syntrix proposes to develop a MetaMorph technology that completely bypasses biologic and enzymatic sources with novel synthetic mimetics comprising PNA-cyclopeptide heterotetramers. MetaMorphs will be identified using a novel and purely chemical discovery paradigm termed PNA-display. We hypothesize that PNA-display will permit us to screen very large heterotetramer populations and identify at least moderate- to high-affinity mimetics in a facile system. High-affinity MetaMorphs will provide a phosphoprotein detection capability equivalent to that of antibodies and other biologically derived mimetics, but without the disadvantages. The SBIR Phase I proposal is designed to prove the feasibility of using PNA-display to identify at least moderate affinity MetaMorphs. Demonstrating feasibility will set the stage to move into an aggressive Phase II program to develop high-affinity MetaMorphs capable of detecting phosphotyrosine embedded within peptides having numerous different primary sequences. Such a MetaMorph collection will be capable of detecting hundreds of known and unknown phosphoproteins and will be of significant utility in basic science, diagnostics, and efforts to develop drugs that modulate protein kinases and phosphatases.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN A ZEBALA其他文献
JOHN A ZEBALA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN A ZEBALA', 18)}}的其他基金
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis
氨基氨蝶呤是替代甲氨蝶呤治疗银屑病的新策略
- 批准号:
7936724 - 财政年份:2006
- 资助金额:
$ 14.98万 - 项目类别:
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis
氨基氨蝶呤是替代甲氨蝶呤治疗银屑病的新策略
- 批准号:
8020549 - 财政年份:2006
- 资助金额:
$ 14.98万 - 项目类别:
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis
氨基氨蝶呤是替代甲氨蝶呤治疗银屑病的新策略
- 批准号:
7054333 - 财政年份:2006
- 资助金额:
$ 14.98万 - 项目类别:
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis
氨基氨蝶呤是替代甲氨蝶呤治疗银屑病的新策略
- 批准号:
7490872 - 财政年份:2006
- 资助金额:
$ 14.98万 - 项目类别:
Instrumentation For High-Resolution Analysis of Cancer
癌症高分辨率分析仪器
- 批准号:
6856622 - 财政年份:2004
- 资助金额:
$ 14.98万 - 项目类别:
Instrumentation For High-Resolution Analysis of Cancer
癌症高分辨率分析仪器
- 批准号:
6876565 - 财政年份:2004
- 资助金额:
$ 14.98万 - 项目类别:
Instrumentation For High-Resolution Analysis of Cancer
癌症高分辨率分析仪器
- 批准号:
7119192 - 财政年份:2004
- 资助金额:
$ 14.98万 - 项目类别:
Instrumentation For High-Resolution Analysis of Cancer
癌症高分辨率分析仪器
- 批准号:
6584885 - 财政年份:2003
- 资助金额:
$ 14.98万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
酸化ストレス応答アポトーシス誘導蛋白のUCに対する新規Biomarker探索と治療への展開
寻找治疗 UC 的氧化应激反应性凋亡诱导蛋白的新生物标志物并开发治疗方法
- 批准号:
24K11919 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
肝内胆管癌新規Biomarkerの同定及び癌周囲間質を標的とした新規治療開発
鉴定肝内胆管癌的新型生物标志物并开发针对癌周基质的新疗法
- 批准号:
24K19350 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
収縮能が保たれた心不全の機械学習分類とmicroRNAなどのbiomarkerの探索
机器学习对具有保留收缩性的心力衰竭进行分类并搜索 microRNA 等生物标志物
- 批准号:
24K19007 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
- 批准号:
MR/Y019415/1 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Research Grant
Sleep and circadian dysfunction in ageing and neurodegeneration: a life course and biomarker study of the British 1946 birth cohort.
衰老和神经退行性疾病中的睡眠和昼夜节律功能障碍:对英国 1946 年出生队列的生命历程和生物标志物研究。
- 批准号:
MR/Y009452/1 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Fellowship
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)
基于生物标志物的慢性肝病早期诊断平台,以实现个性化治疗(LIVERAIM)
- 批准号:
10087822 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
EU-Funded
Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool
通过在远程患者监测工具中集成数字化生物标志物即时检测,增强 COPD 患者的分层
- 批准号:
10098600 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Collaborative R&D
QuBIE: Quantitative Biomarker Identification for Non-Endoscopic Prediction and Monitoring of Treatment Response in Eosinophilic Oesophagitis
QuBIE:用于非内镜预测和监测嗜酸性食管炎治疗反应的定量生物标志物鉴定
- 批准号:
10083253 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Collaborative R&D
膵癌腫瘍内線維化に着目した術前化学療法効果予測に関する画像biomarkerの確立
建立预测胰腺癌瘤内纤维化术前化疗效果的影像生物标志物
- 批准号:
24K18824 - 财政年份:2024
- 资助金额:
$ 14.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Multi-modal non-invasive biomarker screening for high-risk undiagnosed liver disease
针对高危未确诊肝病的多模式非侵入性生物标志物筛查
- 批准号:
10073169 - 财政年份:2023
- 资助金额:
$ 14.98万 - 项目类别:
Collaborative R&D